SCHEMBL14527337

SCHEMBL14527337

CNC(=O)c1cc(Oc2cccc(C(=O)NNC(=O)c3ccc(C)c(Cl)c3)c2)ccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.51
RET P07949 3/20 0.51
BRAF P15056 7/20 0.50
NR1H2 P55055 1/20 0.48
NR1H3 Q13133 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
POLB P06746 1/20 0.48
RAF1 P04049 3/20 0.46
MAPK14 Q16539 3/20 0.46
PLK4 O00444 2/20 0.46
AURKA O14965 2/20 0.46
MAPK13 O15264 2/20 0.46
MAP4K4 O95819 2/20 0.46
ABL1 P00519 2/20 0.46
LCK P06239 2/20 0.46
FYN P06241 2/20 0.46
LYN P07948 2/20 0.46
SRC P12931 2/20 0.46
RPS6KB1 P23443 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14527300 0.92 KDR (0.54) KDRRETBRAFMEN1KMT2A
SCHEMBL14527328 0.88 KDR (0.56) KDRRETBRAFRAF1MAPK14
SCHEMBL14527324 0.85 KDR (0.52) KDRRETBRAFNR1H2NR1H3
SCHEMBL14527390 0.85 KMT2A (0.54) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL14527336 0.85 NPC1 (0.58) KDRRETBRAFMAPK14PLK4
SCHEMBL6014190 0.84 KDR (0.59) KDRRETBRAFMEN1KMT2A
SCHEMBL14527430 0.84 RET (0.69) KDRRETBRAFMEN1KMT2A
SCHEMBL14527327 0.84 KDR (0.56) KDRRETBRAFRAF1MAPK14
SCHEMBL14527335 0.84 BRAF (0.58) KDRRETBRAFRAF1MET
SCHEMBL14527329 0.84 KDR (0.56) KDRRETBRAFRAF1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093529-A1 Diacylhydrazine derivatives MERCK PATENT GMBH (DE) 2007-04-26 US disclosed
US-20070093529-A1 Diacylhydrazine derivatives MERCK PATENT GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093529-A1 Diacylhydrazine derivatives BRAF, RAF1, NRAS KDR 1543/4885RET 77/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.